Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers

[1] Pallotta S(2008)Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease Expert Rev Gastroenterol Hepatol 2 509-522

[2] Pace F(2003)Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors Biol Pharm Bull 26 386-390

[3] Marelli S(1999)Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole Aliment Pharmacol Ther 13 27-36

[4] Kita T(2006)Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes Eur J Clin Pharmacol 62 113-117

[5] Sakaeda T(2000)CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole Aliment Pharmacol Ther 14 1259-1266

[6] Baba T(2006)Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 Clin Pharmacol Ther 79 144-152

[7] Aoyama N(2005)Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects Acta Pharmacol Sin 26 384-388

[8] Kakumoto M(2001)Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 15 793-803

[9] Kurimoto Y(2004)Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 19 113-122

[10] Kawahara Y(2004)CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2-8

[1] Pallotta S(2008)Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease Expert Rev Gastroenterol Hepatol 2 509-522

[2] Pace F(2003)Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors Biol Pharm Bull 26 386-390

[3] Marelli S(1999)Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole Aliment Pharmacol Ther 13 27-36

[4] Kita T(2006)Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes Eur J Clin Pharmacol 62 113-117

[5] Sakaeda T(2000)CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole Aliment Pharmacol Ther 14 1259-1266

[6] Baba T(2006)Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 Clin Pharmacol Ther 79 144-152

[7] Aoyama N(2005)Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects Acta Pharmacol Sin 26 384-388

[8] Kakumoto M(2001)Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 15 793-803

[9] Kurimoto Y(2004)Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 19 113-122

[10] Kawahara Y(2004)CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2-8